-
Yiling Pharmaceutical Lianhua Qingwen Capsules obtained the Liberia drug & health product registration certificate
Time of Update: 2022-05-03
On January 27, Yiling Pharmaceutical issued an announcement saying that Lianhua Qingwen Capsules had obtained the Liberia drug & health care product registration certificate, and the company was qualified to sell the product as an OTC drug in the Liberian market.
-
Jilin Aodong Shengmai Yin (Dangshenfang) obtained the approval notice for supplementary drug application
Time of Update: 2022-05-03
The functions and indications of Shengmaiyin (Dangshenfang): invigorating Qi, nourishing yin and producing body fluid .
Used for deficiency of both qi and yin, palpitations, shortness of breath, and spontaneous perspiration .
-
Junshi Biosciences completes the first patient dosing in the JUPITER-15 study of toripalimab
Time of Update: 2022-05-03
Li Guoxin from Nanfang Hospital of Southern Medical University Led the lead, aiming to evaluate the clinical efficacy and safety of toripalimab versus placebo combined with standard chemotherapy as postoperative adjuvant therapy for patients with gastric or esophagogastric junction adenocarcinoma after radical resection.
-
Rundu Pharmaceutical Itopride Hydrochloride Tablets Obtained Drug Registration Approval
Time of Update: 2022-05-03
On February 17, Rundu Pharmaceutical announced that the company has recently received the "Drug Registration Approval" for itopride hydrochloride tablets issued by the State Drug Administration .
-
Yifan Pharmaceutical's application for registration and marketing authorization for phenylephrine hydrochloride injection was accepted
Time of Update: 2022-05-03
received the domestic registration and listing of phenylephrine hydrochloride injection issued by the State Food and Drug Administration on February 16, 2022.
is listed on the market for phenylephrine injection.
-
The negative controversy of the JAK inhibitor continues, and its Opzelura is still a great success after the launch
Time of Update: 2022-05-03
Incyte Chief Executive Herve Hoppenot said Tuesday that the launch of Opzelura has been "extremely successful" so far, with the topical cream reaching nearly 19,000 patients in the fourth quarter after its official launch in mid-October, with 500 sales.
-
Zai Lab's ROS1/NTRK targeted inhibitor included in breakthrough therapy
Time of Update: 2022-05-03
According to an earlier Zai Lab press release, the Phase 2 registrational portion of the TRIDENT-1 study is a multicenter study evaluating repotrectinib in patients with ROS1-positive advanced NSCLC and in patients with NTRK-positive advanced solid tumors .
-
FDA grants Bayer's oral FXIa inhibitor asundexian Fast Track designation!
Time of Update: 2022-05-03
asundexian is an oral factor XIa (FXIa) inhibitor currently being developed as a potential drug for secondary prevention in patients with NCIS, as well as 2 other diseases: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack) .
-
Sinopharm Modern Cefixime Capsules and Cefaclor Dry Suspension Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-03
Up to now, Sinopharm Zhijun has invested approximately RMB 27 million in R&D (unaudited) for the consistency evaluation of cefixime capsules (0.
Up to now, Sinopharm Zhijun has invested approximately RMB 22 million (unaudited) in research and development for the consistency evaluation of cefaclor dry suspension (0.
-
China Antibody Pharmaceutical's IND application for anti-IL-17RB antibody accepted by FDA
Time of Update: 2022-05-03
(hereinafter referred to as "China Antibody Pharmaceuticals") announced that the company has submitted a new drug clinical trial application (IND) for the anti-IL-17RB monoclonal antibody SM17 to the US FDA, and has It has been accepted by the FDA and is intended to be developed for the treatment of asthma .
-
Introduced by Hutchison Medicine!
Time of Update: 2022-05-03
TextPharmaceutical GuanlanAccording to the China Drug Clinical Trial Registration and Information Publicity Platform, Epizyme has launched an international multi-center (including China) Phase 3 clinical trial of tazemetostat in the treatment of relapsed/refractory follicular lymphoma .
-
The products of 8 companies including Chongqing Yaoyou, Suicheng Pharmaceutical, and Sihuan Kebao have been cancelled!
Time of Update: 2022-05-03
”After verification and confirmation, for products that fail to declare the lowest price in the country as required, their qualifications to be listed on the Internet shall be cancelled and recorded in the integrity file of the enterprise .
-
Han Yuewei, director of China Resources Shuanghe, resigns
Time of Update: 2022-05-03
On February 14, China Resources Shuanghe announced that due to work arrangements, Han Yuewei applied for his resignation as a director and member of the special committee of the ninth board of directors of the company .
-
Another pharmaceutical company discloses 2021 annual performance forecast
Time of Update: 2022-05-02
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
-
Embarrassing 1.2 new Chinese medicines
Time of Update: 2022-05-02
” This point of view is a good description of the different research and development paths of traditional Chinese medicine compound preparations and innovative drugs 1.
2 new traditional Chinese medicines are approved in accordance with the current drug registration management measures.
-
The abuse of antibiotics at the grassroots level is more than the harm of the abuse of antibiotics?
Time of Update: 2022-05-02
Moxifloxacin, as a fourth-generation quinolone broad-spectrum antibacterial drug, has been mainly used in large hospitals for patients with pulmonary infection in recent years, that is, when ordinary antibiotics are ineffective .
But this patient was only on moxifloxacin for a common upper respiratory tract infection .
-
78 drugs from 21 pharmaceutical companies took the initiative to cut prices, with a drop of over 60%!
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
-
Panoramic Interpretation of China's Clinical Trial Application Trends in 2021
Time of Update: 2022-05-02
During this period, the number of core clinical trials carried out in the United States has stabilized at more than 200 per year, while the core clinical development of Chinese companies has increased rapidly since 2017.
-
Sanjitang glimepiride was disqualified from being selected as a substitute for Conquer Pharmaceuticals
Time of Update: 2022-05-02
On February 23, Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement saying that the glimepiride tablets produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
-
Traditional Chinese medicine innovation, and then welcome heavy benefits!
Time of Update: 2022-05-02
In its reply, the State Food and Drug Administration stated that it would actively explore the establishment of a horizontal linkage mechanism and establish a research and development model of "clinical experience prescription - medical institution preparation - new traditional Chinese medicine".
